Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00946712 · ClinicalTrials.gov registry record · Phase 3
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,333
- Enrollment target
NCT00946712 is a Phase 3 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 1,333 participants.
The verdict
NCT00946712, a Phase 3 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,333 participants
- Enrollment target
Study Summary
This randomized phase III trial studies carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or non-small cell lung cancer that has returned after a period of improvement (recurrent). Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may prevent the growth of new blood vessels that tumor needs to grow. Cetuximab may also stop cancer cells from growing by binding and interfering with a protein on the surface of the tumor cell that is needed for tumor growth. It is not yet known whether giving carboplatin and paclitaxel are more effective with or without bevacizumab and/or cetuximab in treating patients with non-small cell lung cancer.
Interventions
- DRUG Carboplatin
- BIOLOGICAL Cetuximab
- OTHER Laboratory Biomarker Analysis
- DRUG Paclitaxel
- BIOLOGICAL Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,333 participants |
| Start Date | 2009-07-15 |
| Est. Completion | 2022-02-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00946712
The ClinicalTrials.gov registry entry for NCT00946712 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,333 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT00946712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00946712 about?
NCT00946712 is a clinical study titled "S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer". This randomized phase III trial studies carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or non-small cell lung cancer that has returned after a period of improvement (recurrent). Drugs used in chemotherapy, such...
What is the current status of trial NCT00946712?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,333 participants. The study started on 2009-07-15. Estimated completion is 2022-02-08.
What interventions are being tested in trial NCT00946712?
The interventions under investigation include: Carboplatin (DRUG), Cetuximab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Paclitaxel (DRUG), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00946712?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.